Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Accentia Biopharmaceuticals has signed a strategic agreement with Baxter Healthcare for the exclusive, worldwide rights of cyclophosphamide, which is marketed under the brand name Cytoxan, for the treatment of designated autoimmune diseases including multiple sclerosis.
Subscribe to our email newsletter
Cyclophosphamide is the active drug used in Revimmune therapy, Accentia‘s proprietary system-of-care being developed for the treatment of a broad range of autoimmune diseases.
The agreement also grants Accentia with the exclusive right for designated indications to reference Baxter‘s proprietary, historical data related to cyclophosphamide as part of Accentia’s planned clinical and regulatory development of Revimmune.
The agreement designates Baxter as Accentia’s sole source of cyclophosphamide for Revimmune.
Baxter Therapeutic Oncology Area Leader Debasis Chakrabarti said that through this agreement, they will be able to support Accentia Biopharmaceuticals in the ongoing development of Revimmune.
Accentia president Samuel Duffey said that they consider their agreement with Baxter to be highly strategic to Accentia’s plans for the development and commercialisation of Revimmune.
"With this agreement in place, we are planning a clinical and regulatory development strategy to advance our mission to establish Revimmune as a new treatment for patients suffering from autoimmune diseases, including orphan indications with potential accelerated regulatory pathways, as well as major indications such as multiple sclerosis," Duffey said.